These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 37311358)

  • 1. The epidemiology of ketosis and low bicarbonate concentration in inpatients treated with sodium-glucose linked cotransporter inhibitors or dipeptidyl peptidase-4 inhibitors.
    Huang W; Whitelaw J; Kishore K; Neto AS; Holmes NE; Marhoon N; Bellomo R; Ekinci EI
    J Diabetes Complications; 2023 Aug; 37(8):108522. PubMed ID: 37311358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Sodium-Glucose Cotransporter-2 Inhibitor and Dipeptidyl Peptidase-4 Inhibitor on the Risks of New-Onset Atrial Fibrillation, Stroke and Mortality in Diabetic Patients: A Propensity Score-Matched Study in Hong Kong.
    Lee S; Zhou J; Leung KSK; Wai AKC; Jeevaratnam K; King E; Liu T; Wong WT; Chang C; Wong ICK; Cheung BMY; Tse G; Zhang Q
    Cardiovasc Drugs Ther; 2023 Jun; 37(3):561-569. PubMed ID: 35142921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New-onset syncope in diabetic patients treated with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors: a Chinese population-based cohort study.
    Gao X; Zhang N; Lu L; Gao T; Chou OHI; Wong WT; Chang C; Wai AKC; Lip GYH; Zhang Q; Tse G; Liu T; Zhou J
    Eur Heart J Cardiovasc Pharmacother; 2024 Feb; 10(2):103-117. PubMed ID: 37962962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary Occurrence of Cardiovascular Events After Adding Sodium-Glucose Cotransporter-2 Inhibitors or Glucagon-like Peptide-1 Receptor Agonists Compared With Dipeptidyl Peptidase-4 Inhibitors: A Cohort Study in Veterans With Diabetes.
    Richardson TL; Halvorson AE; Hackstadt AJ; Hung AM; Greevy R; Grijalva CG; Elasy TA; Roumie CL
    Ann Intern Med; 2023 Jun; 176(6):751-760. PubMed ID: 37155984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study.
    Chan YH; Chao TF; Chen SW; Lee HF; Li PR; Chen WM; Yeh YH; Kuo CT; See LC; Lip GYH
    Cardiovasc Diabetol; 2022 Jun; 21(1):118. PubMed ID: 35765074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of acute increases in serum creatinine with subsequent outcomes in patients with type 2 diabetes mellitus treated with sodium-glucose cotransporter 2 inhibitor or dipeptidyl peptidase-4 inhibitor.
    Chan YH; Chao TF; Chen SW; Kao YW; Huang CY; Chu PH
    Eur Heart J Qual Care Clin Outcomes; 2023 Jun; 9(4):397-407. PubMed ID: 35797996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiometabolic risk reductions in patients with type 2 diabetes mellitus newly treated with a sodium-glucose cotransporter 2 inhibitor versus a dipeptidyl peptidase-4 inhibitor: A real-world administrative database study in Japan.
    Kashiwagi A; Shoji S; Kosakai Y; Koga T; Asakawa K; Rokuda M
    J Diabetes Investig; 2023 Mar; 14(3):404-416. PubMed ID: 36515129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incident heart failure and myocardial infarction in sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitor users.
    Zhou J; Lee S; Leung KSK; Wai AKC; Liu T; Liu Y; Chang D; Wong WT; Wong ICK; Cheung BMY; Zhang Q; Tse G
    ESC Heart Fail; 2022 Apr; 9(2):1388-1399. PubMed ID: 35132823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparing sodium-glucose cotransporter 2 inhibitors and dipeptidyl peptidase-4 inhibitors on new-onset depression: a propensity score-matched study in Hong Kong.
    Mui JV; Li L; Chou OHI; Azfar N; Lee A; Hui J; Lee S; Tse G; Zhou J
    Acta Diabetol; 2023 Jul; 60(7):917-927. PubMed ID: 37000300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The comparative epidemiology and outcomes of hospitalized patients treated with SGLT2 or DPP4 inhibitors.
    Huang W; Whitelaw J; Kishore K; Neto AS; Holmes NE; Marhoon N; Bellomo R; Ekinci EI
    J Diabetes Complications; 2021 Dec; 35(12):108052. PubMed ID: 34600824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular, renal, and lower limb outcomes in patients with type 2 diabetes after percutaneous coronary intervention and treated with sodium-glucose cotransporter 2 inhibitors vs. dipeptidyl peptidase-4 inhibitors.
    Lee HF; Chan YH; Chuang C; Li PR; Yeh YH; Hsiao FC; Peng JR; See LC
    Eur Heart J Cardiovasc Pharmacother; 2023 Jun; 9(4):301-310. PubMed ID: 36639127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Sodium-Glucose Cotransporter 2 Inhibitor vs Dipeptidyl Peptidase-4 Inhibitor Use With Risk of Incident Obstructive Airway Disease and Exacerbation Events Among Patients With Type 2 Diabetes in Hong Kong.
    Au PCM; Tan KCB; Lam DCL; Cheung BMY; Wong ICK; Kwok WC; Sing CW; Cheung CL
    JAMA Netw Open; 2023 Jan; 6(1):e2251177. PubMed ID: 36648944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lower risk of gout in sodium glucose cotransporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP4) inhibitors in type-2 diabetes.
    Zhou J; Liu X; Chou OH; Li L; Lee S; Wong WT; Zhang Q; Chang C; Liu T; Tse G; Jing F; Cheung BMY
    Rheumatology (Oxford); 2023 Apr; 62(4):1501-1510. PubMed ID: 36066415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors for new-onset gastric cancer and gastric diseases in patients with type 2 diabetes mellitus: a population-based cohort study.
    Chou OHI; Chauhan VK; Chung CTS; Lu L; Lee TTL; Ng ZMW; Wang KKW; Lee S; Liu H; Pang RTK; Kaewdech A; Cheung BMY; Tse G; Zhou J
    Gastric Cancer; 2024 Sep; 27(5):947-970. PubMed ID: 38856768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular and Renal Outcomes With Sodium-Glucose Cotransporter-2 Inhibitors and Dipeptidyl Peptidase-4 Inhibitors Combination Therapy: A Meta-Analysis of Randomized Cardiovascular Outcome Trials.
    Singh AK; Singh A; Singh R
    Endocr Pract; 2023 Jul; 29(7):509-516. PubMed ID: 37037286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effectiveness of sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors on liver function in patients with type 2 diabetes in Japan: A real-world data analysis.
    Takahashi H; Asakawa K; Kosakai Y; Lee T; Rokuda M
    Diabetes Obes Metab; 2024 Mar; 26(3):997-1007. PubMed ID: 38086547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sodium-glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors on new-onset overall cancer in Type 2 diabetes mellitus: A population-based study.
    Chung CT; Lakhani I; Chou OHI; Lee TTL; Dee EC; Ng K; Wong WT; Liu T; Lee S; Zhang Q; Cheung BMY; Tse G; Zhou J
    Cancer Med; 2023 Jun; 12(11):12299-12315. PubMed ID: 37148547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A short-term follow-up of glycemic and body weight changes in diabetic patients who replaced dipeptidyl peptidase-4 inhibitors with the sodium-glucose cotransporter 2.
    Huang CH; Huang YY; Hsu BR
    Ann Saudi Med; 2018; 38(6):420-426. PubMed ID: 30531176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of combination therapy with SGLT2 and DPP4 inhibitors in the treatment of type 2 diabetes: A systematic review and meta-analysis.
    Cho YK; Kang YM; Lee SE; Lee J; Park JY; Lee WJ; Kim YJ; Jung CH
    Diabetes Metab; 2018 Nov; 44(5):393-401. PubMed ID: 29449146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors.
    Ling AW; Chan CC; Chen SW; Kao YW; Huang CY; Chan YH; Chu PH
    Cardiovasc Diabetol; 2020 Nov; 19(1):188. PubMed ID: 33158436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.